ING secondary Ren Pr Convention PI3K AKT Signaling Pathways Cases of Schlaganf. CILOSTAZOL AS AN ALTERNATIVE TO aspirin after a ish Stroke mix Ver on the results of the LSP Published, the data are still lacking in the cilostazol versus an active comparator. In 2008, Huang and colleagues CASISP, an attempt to treat intentto developed to ensure the safety and efficacy of cilostazol versus aspirin for secondary Rpr Convention Of Schlaganf Fill prevention.15 CASISP was a randomized, double-blind, multicenter Ver judge Published pilot test, the 719 Chinese patients diagnosed with an image ish ischemic stroke were recruited has undergone. Patients were randomized to cilostazol 100 mg orally twice t Resembled aspirin 100 mg orally once or get t Possible after six months of a heart attack. Patients were observed for 12 long 18 months and evaluated on the primary re ultimate goal of recurrent stroke as defined by the following options: Ish Ischemic stroke, hemorrhage, cerebral hemorrhage, or sub-arachno Dian. Patients with a history of subarachnoid hemorrhage arachno Dian, I, cardioembolic stroke, contra-indication for therapy with platelet aggregation inhibitors, other than treatment with antiplatelet agents cilostazol may need during the study period, a severe disability, Komorbidit Th not to use Strips or modified Rankin Scale score of 4 or more are not f Rderf Capable, controls for inclusion in this study. A value of 4 or h Ago on the modified Rankin scale of disability is moderate to severe, including normal patients with no or without the help bettl requires Gerigen patients go to st Requests reference requests getting care and support. A score of 6 to death.24 assigned were 25 specific uncontrollably Strips concomitant diseases and disabilities of patients qualifying for the exclusion of non stated.15 patients with high blood pressure and Fettstoffwechselst Changes at the beginning of the study were given antihypertensives and / or statins. As no specific funds are used, the number of patients in each treatment group to define or criteria, or hypertension Dyslipid Chemistry announced. Baseline characteristics were similar between the two groups. Systolic blood pressure was significantly h initially Forth in the aspirin group Highest. These patients were treated with antihypertensive drugs, with a resolution and high hypertension after one month of therapy. No explanation Use of drugs have been changes, the number of patients for high blood pressure or blood pressure treatment goal made. Sixty-two percent of patients in both groups were taking aspirin before admission. One percent or less of patients in each group was on cilostazol before enrollment. Most patients in both groups had achieved a modified Rankin scale score of 2 or less.15 the prim Ren endpoint of 12 patients in the cilostazol group and 20 patients in the aspirin group, which then only a RRR of 38, 1%. Isch were endemic in 26 patients Schlaganf ll: 11 and 15 cilostazol with aspirin, but this finding did not reach statistical significance. As part of the prime Ren endpoint, h Haemorrhagic Schlaganf Ll accounted for 8% of stroke associated with cilostazol and 25% of stroke associated with aspirin. New micro-hemorrhages and asymptomatic hematoma H Fewer hours Frequently HA-1077 been reported in the cilostazol group than in the aspirin group, however, no testimony of importance was reported. Other side effects that h More frequently in the cilostazol group were headache, dizziness, palpitations and tachycardia. Extracranial haemorrhage was h Reported more frequently.